Antithrombin Market to Grow with a CAGR of 4.67% through 2028
Increasing prevalence of thrombotic disorders to
advancements in biotechnology and pharmaceuticals are expected to drive the
Global Antithrombin Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “Antithrombin
Market – Global Industry Size, Share, Trends, Competition Forecast &
Opportunities, 2028”, the Global Antithrombin Market stood at USD 749.86 million
in 2022 and is anticipated to grow with a CAGR of 4.67% in the forecast period,
2024-2028. This can be attributed to research and development. Research and
development efforts in the field of antithrombin continue to advance. Ongoing
studies explore new therapeutic applications and formulations of antithrombin
products. These innovations offer the potential to expand the market by
addressing unmet medical needs and improving patient outcomes.
Moreover, as patents on some antithrombin products
expire, the market may witness the introduction of biosimilar versions.
Biosimilars, which are highly similar to reference biologic products, could
provide cost-effective alternatives, potentially driving competition and
influencing pricing strategies.
The initial phase of the COVID-19 pandemic had a
significant impact on the antithrombin market due to factors such as the
temporary closure of manufacturing facilities and disruptions in research and
development activities. However, the demand for antithrombin products has seen
a rapid rise in response to their increased use in treating COVID-19 patients.
For instance, a December 2022 report published in Acta Haematologica
highlighted that low antithrombin activity is associated with higher mortality
rates in severe COVID-19 cases, as well as with pro-inflammatory and prolonged
hypercoagulable conditions. Antithrombin, owing to its anti-thromboinflammatory
properties, is becoming a promising focus for future research in combating
COVID-19 infection, and this is expected to drive market growth in the years
ahead.
Several factors are propelling the growth of the
antithrombin market. This includes a growing incidence of coagulation disorders
and the increased use of diagnostic kits employing antithrombin. Antithrombin
plays a pivotal role in preventing excessive blood clotting, and its demand has
surged in surgical procedures, particularly in cases involving chronic
illnesses like heart and kidney diseases. During surgeries, antithrombin is
crucial in preventing the formation of blood clots. Therefore, the upswing in surgical
procedures due to the prevalence of chronic diseases and an uptick in cases of
antithrombin deficiency has led to a heightened demand for antithrombin,
thereby fostering market growth.
For instance, according to a 2022 report by the
British Heart Foundation, 7.6 million individuals in the United Kingdom suffer
from heart and circulatory conditions. Moreover, these numbers are anticipated
to continue rising due to factors such as underlying heart and circulatory
issues, an aging and expanding population, among others. Consequently, the
substantial burden of heart and circulatory diseases is driving the demand for
surgical interventions, consequently increasing the usage of antithrombin and
serving as a catalyst for market growth during the study period.
Furthermore, in December 2022, Octapharma announced
the ATN-06 study, which investigates the use of Atenativ, a Plasma-Derived
Antithrombin Concentrate, in individuals with congenital antithrombin
deficiency undergoing surgery or childbirth. These new studies focusing on
antithrombin deficiency treatments are poised to stimulate the demand for
antithrombin drugs, further augmenting market growth in the forecast period.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Antithrombin Market”
The Global Antithrombin Market is segmented into
usage, source, type, regional distribution, and company.
Based on its usage, it is anticipated that the
Therapeutics Segment will dominate the market share significantly throughout
the projected period. Antithrombin serves as a viable treatment option in
scenarios such as cardiac surgeries and genetic conditions like hereditary antithrombin
deficiency. This hereditary condition, also known as antithrombin III
deficiency or AT III deficiency, puts individuals at a higher risk of
developing blood clots and various heart ailments. Roughly 50% of those
afflicted with hereditary antithrombin deficiency will experience one or more
clotting events in their lifetime, typically occurring after adolescence,
necessitating appropriate treatment with antithrombin. As a result, this
segment is poised to be the driving force behind market growth during the study
duration.
Moreover, ongoing research efforts into the treatment
of various antithrombin deficiencies have the potential to expand the
applications of various drugs and bolster market expansion over the study
period. For instance, a research report published by the Thrombosis Update
journal in December 2021 recommended the use of low molecular weight heparin
(LMWH) in pregnancy, along with regular anti-Xa monitoring, to ensure that
women receive adequate antithrombotic therapy. Given the efficacy of LMWH in
activating antithrombin, individuals with antithrombin deficiency often require
substantial doses of LMWH. Consequently, with these new research findings, the
utilization of antithrombin drugs is expected to increase, further propelling
market growth during the study period.
Based on region, the Asia-Pacific region is poised to
experience rapid growth in the forthcoming forecast period. This upswing can be
attributed to the burgeoning adoption of innovative medical treatments and
techniques in developing nations like India and China, aimed at combatting a
spectrum of diseases. The escalating disposable incomes in these emerging
economies, coupled with their heightened capacity to invest in advanced
healthcare solutions, create fertile ground for market opportunities in the
Asia-Pacific region. Moreover, the increasing burden of an aging population,
along with a rising incidence of thrombosis-related ailments and ongoing
research into antithrombin deficiency within the region, is expected to be a
driving force behind market growth throughout the forecast period.
Notably, the expanding elderly population in India
plays a pivotal role in propelling the market in this region. According to data
from the NSO, the proportion of elderly individuals in India was projected to
reach 10.1% in 2021 and is forecasted to rise to 13.1% by 2031. With this
demographic shift, the risk of thrombosis increases substantially, resulting in
a heightened demand for antithrombin treatments, which, in turn, stimulates
market growth.
Major companies operating in Global Antithrombin Market
are:
- CSL Ltd
- Grifols SA
- Takeda Pharmaceutical Co Ltd
- Octapharma AG
- LFB USA
- Endpoint Health, Inc.
- Siemens Healthcare GmbH
- Thermo Fisher Scientific Inc
- Oy Medix Biochemica Ab
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The global antithrombin market is on the brink of
transformation, driven by emerging trends that promise to enhance patient care
and expand the scope of antithrombin therapies. Personalized medicine, novel
therapeutic indications, enhanced formulations, telemedicine, biosimilars,
increased research and development, regulatory changes, and growing patient
advocacy and awareness are among the key trends that will shape the market's
future. As these trends continue to unfold, the global antithrombin market is
poised to provide more effective and accessible treatments for thrombotic
disorders, ultimately improving the quality of life for patients worldwide,”
said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based management consulting firm.
“Antithrombin Market By Usage
(Therapeutics, Diagnostics, Research, Others), By Source (Human, Recombinant
Goat Milk, Others), By Type (Anticoagulant, Antiplatelet, Thrombolytic Drugs), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Antithrombin Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Antithrombin Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com